The psychedelics industry is approaching a significant milestone, with growing clinical evidence and increasing policy support, according to Graig Suvannavejh, managing director at Mizuho Securities, in an Aug. 10 email interview.
Suvannavejh said the sector is experiencing "rational exuberance" as it awaits broader acceptance of psychedelic therapies. He noted that excitement continues to grow each year despite concerns about safety and abuse risk. "Doctors and patients are eager for new psychiatric treatment options that are more effective and faster-acting than current drugs," Suvannavejh said.
Recent industry developments include Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, targeting a synthetic psychedelic for treatment-resistant depression (TRD). While some analysts view this move as validation from major pharmaceutical companies, others remain cautious about its broader implications. Paul Matteis of Stifel said there is "a lot of enthusiasm," but also "some trepidation" regarding the scalability of these treatments in clinical practice. Matteis added that the acquisition demonstrates societal acceptance has advanced significantly.
Jama Pitman, strategic advisor at Rose Hill Life Sciences, highlighted historical barriers: “The drugs were there, the science was there, the medical need was there—we were just unable to move the field forward because of laws that prohibited it and the associated stigma.” She now sees widespread agreement among policymakers and clinicians that psychedelics may be effective when properly administered.
Patrick Trucchio from H.C. Wainwright & Co. acknowledged existing psychiatric medications such as SSRIs remain useful but pointed out their limitations: millions with TRD do not achieve remission even after multiple treatments. Recent clinical data from Compass Pathways and Definium Therapeutics have shown positive results for psychedelic-based therapies in depression trials—often requiring only one or a few doses compared to ongoing medication regimens.
Policy changes have supported this momentum; President Donald Trump issued an executive order directing expedited review programs at the Food and Drug Administration (FDA), which recently awarded priority vouchers to several psychedelic developers. Health Secretary Robert F. Kennedy Jr., described by Suvannavejh as “a long-time supporter,” has promoted natural remedies through Department of Health and Human Services initiatives focused on reassessing psychiatric prescribing patterns.
Despite progress, challenges remain such as functional unblinding in trials—where patients can tell if they received a placebo or active drug—and regulatory scrutiny over side effects like suicidality or addiction risk. Trucchio recommended robust trial controls, while Andrew Tsai from Jefferies said companies are taking these issues seriously with strictly controlled studies and government engagement on trial management protocols.
